MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41598-020-80063-0

Медицинская библиотека · Scientific reports · 2021

Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice.

Zhang Wenchao, Miikeda Aika, Zuckerman Jonathan, Jia Xun, Charugundla Sarada, Zhou Zhiqiang, Kaczor-Urbanowicz Karolina Elżbieta, Magyar Clara, Guo Fangfei, Wang Zeneng, Pellegrini Matteo, Hazen Stanley L, Nicholas Susanne B, Lusis Aldons J, Shih Diana M

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Patients with chronic kidney disease (CKD) have elevated circulating levels of trimethylamine N-oxide (TMAO), a metabolite derived from gut microbes and associated with cardiovascular diseases. High circulating levels of TMAO and its dietary precursor, choline, predict increased risk for development of CKD in apparently healthy subjects, and studies in mice fed TMAO or choline suggest that TMAO can contribute to kidney impairment and renal fibrosis. Here we examined the interactions between TMAO, kidney disease, and cardiovascular disease in mouse models. We observed that while female hyperlipidemic apoE KO mice fed a 0.2% adenine diet for 14 weeks developed CKD with elevated plasma levels of TMAO, provision of a non-lethal inhibitor of gut microbial trimethylamine (TMA) production, iodomethylcholine (IMC), significantly reduced multiple markers of renal injury (plasma creatinine, cystatin C, FGF23, and TMAO), reduced histopathologic evidence of fibrosis, and markedly attenuated development of microalbuminuria. In addition, while the adenine-induced CKD model significantly increased heart weight, a surrogate marker for myocardial hypertrophy, this was largely prevented by IMC supplementation. Surprisingly, adenine feeding did not increase atherosclerosis and significantly decreased the expression of inflammatory genes in the aorta compared to the control groups, effects unrelated to TMAO levels. Our data demonstrate that inhibition of TMAO production attenuated CKD development and cardiac hypertrophy in mice, suggesting that TMAO reduction may be a novel strategy in treating CKD and its cardiovascular disease complications.

Для цитирования: Zhang Wenchao, Miikeda Aika, Zuckerman Jonathan, Jia Xun, Charugundla Sarada, Zhou Zhiqiang, Kaczor-Urbanowicz Karolina Elżbieta, Magyar Clara, Guo Fangfei, Wang Zeneng, Pellegrini Matteo, Hazen Stanley L, Nicholas Susanne B, Lusis Aldons J, Shih Diana M. Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice.. Scientific reports. 2021. DOI: 10.1038/s41598-020-80063-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.